4.7 Review

Cardiac arrhythmias and conduction defects in systemic sclerosis

期刊

RHEUMATOLOGY
卷 53, 期 7, 页码 1172-1177

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/ket377

关键词

systemic sclerosis; arrhythmias; conduction defects; cardiac involvement; mortality

资金

  1. Actelion
  2. Pfizer
  3. Ergonex
  4. BMS
  5. Sanofi-Aventis
  6. United BioSource
  7. Roche/Genentech
  8. Medac
  9. Biovitrium
  10. Boehringer Ingelheim Pharma
  11. Novartis
  12. 4D Science
  13. Active Biotec
  14. Sinoxa
  15. Serodapharm
  16. National Institutes of Health/NIAMS [K24 AR063120]

向作者/读者索取更多资源

Signs and symptoms of arrhythmias or conduction defects are frequently reported in patients with SSc. These rhythm disorders may have several origins (i.e. related to primary heart involvement, pericardial disease, valvular regurgitation or pulmonary arterial hypertension) and may negatively affect the overall prognosis of these patients. It is therefore important to identify patients at high risk for cardiac arrhythmias with a complete cardiological evaluation and to identify the underlying heart disease, including SSc-related myocardial involvement. In addition, some therapeutic options in SSc patients may differ from those recommended in other populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据